FrancophonIA/ELRC3.0 huggingface dataset:
English: Pregnancy Yttrium (90Y)-labelled medicinal products are contraindicated in established or suspected pregnancy or when pregnancy has not been excluded (see section 4.3).
Estonian: Rasedus Ütriumiga (90Y) märgistatud ravimid on vastunäidustused teadaoleva raseduse ja raseduse kahtluse korral või kui raseduse võimalus ei ole välistatud (vt lõik 4.3).
English: 1 g of the chelating agents should be administered by slow intravenous injection over 3 - 4 minutes or by infusion (1 g in 100 - 250 ml of dextrose, or normal saline).
Estonian: 1 g kelaate moodustavat ainet tuleb manustada aeglase 3 - 4-minutilise intravenoosse süste või infusiooni teel (1 g 100 - 250 ml dekstroosi või füsioloogilise soolalahuse kohta).
English: The contents of the vial of Yttriga is not to be administered directly to the patient but must be used for the radiolabelling of carrier molecules, such as monoclonal antibodies, peptides or other substrates.
Estonian: Yttriga viaali sisu ei tohi manustada patsiendile otse, vaid sellega radiomärgistatakse kandjamolekule (nt monoklonaalsed antikehad, peptiidid või muud substraadid).
English: Do not administer Yttriga directly to the patient.
Estonian: Ärge manustage Yttriga't patsiendile otse.
English: ANNEX II A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Estonian: LISA II A. TOOTMISLOA HOIDJA, KES VASTUTAB RAVIMIPARTII VABASTAMISE EEST
English: At 1 and 24 hours, blood radioactivity decreases from 11.0 % to 0.14 % of the administered activity.
Estonian: Veres olev radioaktiivsus oli 1. tunnil 11,0 %, mis vähenes 24 tunni möödudes 0,14 %-le manustamisaegsest aktiivsusest.
English: Yttriga is only to be used by specialists experienced with in vitro radiolabelling.
Estonian: Yttriga't tohivad kasutada ainult in vitro radiomärgistamise kogemusega arstid.
English: The following preparations must be available in medical institutions, which use Yttriga for labelling of carrier molecules for therapeutic purposes: - Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or - Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Estonian: Yttriga't terapeutilisel eesmärgil kandjamolekulide märgistamisel kasutatavates haiglates peavad olema saadaval järgmised preparaadid: - Ca-DTPA (trinaatriumkaltsiumdietüleentriamiinpentaatsetaat) või - Ca-EDTA (kaltsiumdinaatriumetüleentriamiintetraatsetaat).
English: It is important that all glassware, syringe needles etc, used for the preparation of the radiolabelled medicinal product are thoroughly cleaned to ensure freedom from such trace metal impurities.
Estonian: Kõik radiomärgistatava preparaadi ettevalmistamisel kasutatavad klaasvahendid, süstlanõelad jne tuleb hoolikalt puhastada, et neile ei jääks metallijääkide jälgi.
English: In any case the blood parameters of the patient have to be monitored and the appropriate actions immediately taken if there is evidence of damage to the blood marrow.
Estonian: Kõikidel juhtudel tuleb jälgida patsiendi verenäitajaid ja luuüdi kahjustusnähtude ilmnemisel võtta koheselt kasutusele vastavad meetmed.
English: Radiopharmaceutical precursor - Not intended for direct use in patients.
Estonian: Radiofarmatseutiline prekursor - mitte manustada patsiendile otse.
English: It decays by emission of beta radiation of 2.281 MeV (99.98 %) of maximal energy to stable Zirconium (90Zr).
Estonian: Lagunemine toimub tsirkooniumi (90Zr) stabiliseerimiseks vajaliku 2,281 MeV (99,98 %) maksimaalenergia beetakiirguse emissioonil.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/05/322/001 (3 ml V-shaped vial) EU/1/05/322/002 (10 ml flat bottom vial)
Estonian: EU/1/05/322/001 (3 ml V-kujulise põhjaga viaal) EU/1/05/322/002 (10 ml lameda põhjaga viaal)
English: Colourless type I glass vial of 3 ml with a V-shapped bottom or a colourless type I glass vial of 10 ml with a flat bottom with a silicon stopper, closed with an aluminium seal.
Estonian: V-kujulise põhjaga värvitu I tüüpi klaasist 3 ml viaal või lameda põhjaga värvitu I tüüpi klaasist 10 ml viaal silikoonkorgiga, mis on suletud alumiiniumkattega.
English: The product should be aseptically withdrawn through the stopper using sterilised single use needle and syringe after disinfecting the stopper.
Estonian: Preparaat tuleb läbi kummikorgi aseptiliselt välja tõmmata, kasutades steriliseeritud ühekordset süstalt ja süstlanõela ning olles eelnevalt korgi desinfitseerinud.
English: No interactions of Yttrium (90Y) chloride with other medicines are known as no clinical studies are available.
Estonian: Ütriumkloriidi (90Y) koostoimeid teiste ravimitega ei teata, sest kliinilisi uuringuid ei ole.
English: The activity administered must be such that the resulting radiation dose is as low as reasonably achievable bearing in mind the need to obtain the intended therapeutic result.
Estonian: Manustatav aktiivsus tuleb valida nii, et lõppdoos oleks võimalikult väike, kuid samas peab see tagama soovitud terapeutilise tulemuse.
English: What Yttriga is and what it is used for Before you use Yttriga How to use Yttriga.
Estonian: Mis ravim on Yttriga ja milleks seda kasutatakse Mida on vaja teada enne Yttriga kasutamist Kuidas Yttriga't kasutada Võimalikud kõrvaltoimed Kuidas Yttriga't säilitada Lisainfo
English: The radiation dose resulting from therapeutic exposure may result in higher incidence of cancer and mutations.
Estonian: Terapeutilise ekspositsiooniga kaasnev kiiritusdoos võib suurendada vähi ja mutatsioonide sagedust.
English: HOW TO USE YTTRIGA
Estonian: KUIDAS YTTRIGA'T KASUTADA
English: Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects.
Estonian: Ekspositsiooni ioniseerivale kiirgusele seostatakse vähkkasvajate ja pärilike väärarengute tekkeohuga.
English: Therefore, in case of an inadvertent administration of Yttriga, the radiotoxicity for the patient must be reduced by immediate (i. e. within 1 hour) administration of preparations containing chelators like CaDTPA or Ca-EDTA in order to increase the elimination of the radionuclide from the body.
Estonian: Seetõttu tuleb Yttriga tahtmatu manustamise korral radiotoksilisust vähendada, manustades viivitamatult (st 1 tunni vältel) kelaatoreid (nt Ca- DTPA või Ca-EDTA) sisaldavaid preparaate, et viia radionukliid organismist välja.
English: Act.: (Y) GBq/vial
Estonian: : (Y) GBq/viaal
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL LABEL ON PERSPEX SHIELD
Estonian: MINIMAALSED NÕUDED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL VIAALI ETIKETT PLEKSIKLAASIL
English: Imaging Equipment Limited The Barn, Manor Farm, Church Lane Chilcompton, Somerset BA3 4 HP SalesAdmin@imagingequipment.co.uk
Estonian: Imaging Equipment Limited The Barn, Manor Farm, Church Lane Chilcompton, Somerset BA3 4 HP
English: Fax +49- 30-941084-470 e-mail: radiopharma@ezag.de
Estonian: tel +49- 30-941084-280 faks +49- 941084-470 e-mail: radiopharma@ezag.de
English: Radiolabelling of medicinal products, such as monoclonal antibodies, peptides or other substrates, with Yttrium (90Y) chloride is very sensitive to the presence of trace metal impurities.
Estonian: Ravimipreparaatide, nagu monoklonaalsete antikehade, peptiidide ja teiste substraatide radiomärgistamine ütriumkloriidiga (90Y) on kergesti mõjutatav metallijääkide olemasolu poolt.
English: INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS Before use, packaging and radioactivity should be checked.
Estonian: Enne kasutust tuleb kontrollida pakendit ja radioaktiivsust.
English: Yttriga is a radioactive medicine used in combination with another medicine which targets specific body cells.
Estonian: Yttriga on radioaktiivne ravim, mida kasutatakse koos spetsiifiliste keharakkude vastu suunatud teise ravimiga.
English: Hydrochloric acid (0.04 M)
Estonian: Vesinikkloriidhape (0,04 M).
English: Yttrium (90Y) is a beta pure emitter.
Estonian: Ütrium (90Y) on puhas beetakiirgus.
English: EXP {MM/YYYY} (12h CET)
Estonian: : {PP/KK/AAAA} (12 h CET)
English: Yttrium (90Y) chloride is produced by decay of its radioactive precursor Strontium (90Sr).
Estonian: Ütriumkloriid (90Y) saadakse selle radioaktiivse lähteaine strontsiumi (90Sr) lagunemisel.
English: HOW TO STORE YTTRIGA
Estonian: KUIDAS YTTRIGA'T SÄILITADA
English: A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Estonian: A TOOTMISLOA HOIDJA, KES VASTUTAB RAVIMIPARTII VABASTAMISE EEST
English: (corresponding to 0.005-15 micrograms of Yttrium [90Y]) (as Yttrium [90Y] chloride).
Estonian: 0,005-15 mikrogrammile ütriumile [90Y]) (ütriumkloriidina [90Y]).
English: Yttrium (90Y)-labelled medicinal products are contraindicated in the following case:
Estonian: Ütriumiga (90Y) märgistatud ravimite kasutamine on vastunäidustatud järgmistel juhtudel:
English: Radiation protection precautions in accordance with national regulations must therefore be taken.
Estonian: Seetõttu tuleb tarvitusele võtta kohalikele nõuetele vastavad kiirguskaitse ettevaatusabinõud.
English: The toxicity of the free Yttrium (90Y) due to in-vivo release from the labelled biomolecule in the body during therapy could be reduced by post-administration of chelating agents.
Estonian: Vaba ütriumi (90Y) toksilisus märgistatud biomolekulist in vivo vabanemise tõttu ravi ajal saab vähendada, kui manustada kelaativaid aineid.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL
Estonian: MINIMAALSED NÕUDED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL VIAAL
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Yttriga solution
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Yttriga lahus
English: To be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.
Estonian: Lahusega tohib radiomärgistada ainult kandjamolekule, mis on spetsiaalselt selle radionukliidiga radiomärgistamiseks välja töötatud ja mille sobivus on kinnitatud.
English: Absorbed dose per unit activity administered (mGy/MBq)
Estonian: Neeldumisdoos manustatud aktiivsusühiku kohta (mGy/MBq)
English: 1 year (10 kg)
Estonian: 1 aasta (10 kg)
English: In the rat, following intravenous administration, Yttrium (90Y) chloride is rapidly cleared from the blood.
Estonian: Rottidel elimineerub intravenoosselt manustatud ütriumkloriid (90Y) verest kiiresti.
English: METHOD OF ADMINISTRATION For in vitro radiolabelling.
Estonian: In vitro radiomärgistamiseks.
English: Take special care with Yttriga - Yttriga is a radioactive medicine and is only used in combination with another medicinal product.
Estonian: Yttriga on radioaktiivne ravim ja seda kasutatakse ainult koos teise ravimiga.
English: It is not intended for direct use in patients.
Estonian: Yttriga ei ole ette nähtud patsientidele otse manustamiseks.
English: The presence of free Yttrium (90Y) chloride in the body after an inadvertent administration of Yttriga will lead to increased bone marrow toxicity and haematopoietic stern cell damage.
Estonian: Yttriga tahtmatu manustamise järel organismi sattunud vaba ütriumkloriid (90Y) suurendab luuüdi toksilisust ja vereloome tüvirakkude kahjustumist.
English: Pack size: 1 vial Not all presentations may be marketed.
Estonian: Kõik pakendi suurused ei pruugi olla müügil.
English: 15 years (50 kg)
Estonian: 15 aastat (50 kg)
English: Clear colourless solution, free of particulate matter.
Estonian: Selge, värvitu lahus, mis ei sisalda osakesi.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml sterile solution contains 0.1-300 GBq Yttrium (90Y) on the reference date and time (corresponding to 0.005-15 micrograms of Yttrium [90Y]) (as Yttrium [90Y] chloride).
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS 1 ml steriilset lahust sisaldab referentskuupäeval ja -kellaajal 0,1-300 GBq ütriumi (90Y) (vastab 0,005-15 mikrogrammile ütriumile [90Y]) (ütriumkloriidina [90Y]).
English: Only syringe needles (for example, non-metallic) with proven resistance to dilute acid should be used to minimise trace metal impurity levels.
Estonian: Et metallijääkide olemasolu minimeerida, tohib kasutada ainult lahjendatud happele tõestatult resistentseid süstlanõelu (nt mittemetalseid).
English: 5 years (17 kg)
Estonian: 5 aastat (17 kg)
English: Specific activity at calibration: (Y) GBq/vial
Estonian: : {PP/KK/AAAA} (12 h CET) Spetisiifiline aktiivsus kalibratsioonil: (Y) GBq/viaal
English: Radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings and receipt, storage, use, transfer and disposal are subject to the regulations and appropriate licences of the competent authorities.
Estonian: Preparaadi üleandmine, säilitamine, transport ja hävitamine peavad vastama pädevate ametkondade määrustele ja olema varustatud vastavate litsentsidega.
English: Adult (70 kg)
Estonian: Täiskasvan u (70 kg)
English: - The active substance is Yttrium (90Y) chloride.
Estonian: Mida Yttriga sisaldab - Toimeaine on ütriumkloriid (90Y).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Yttrium (90Y) chloride
Estonian: TOIMEAINE(TE) SISALDUS Ütriumkloriid (90Y)
English: 10 years (30 kg)
Estonian: 10 aastat (30 kg)
English: In the liver, 18 % of the injected activity is taken up 5 min after injection.
Estonian: Maksa jõuab 5 minuti jooksul pärast süstimist 18% süstitud aktiivsusest.
English: EU/1/05/322/002
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/05/322/002
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Yttriga radiopharmaceutical precursor, solution.
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Yttriga radiofarmatseutiline prekursor, lahus.
English: Store in accordance with local regulations for radioactive substances.
Estonian: Hoida kooskõlas radioaktiivseid aineid puudutavate kohalike seadustega.
English: Yttrium (90Y) chloride
Estonian: Ütriumkloriid (90Y)
English: Newborn (5 kg)
Estonian: Vastsündin u (5 kg)
English: Yttriga radiopharmaceutical precursor, solution.
Estonian: Yttriga radiofarmatseutiline prekursor, lahus.
English: - The other ingredient is hydrochloric acid (0.04 M).
Estonian: - Abiaine on vesinikkloriidhape (0,04 M).
English: Ask your doctor or pharmacist for advice before taking any medicine.
Estonian: Enne ravimi kasutamist pidage nõu arsti või apteekriga
English: Women of childbearing potential Women of childbearing potential have to use effective contraception during and after treatment.
Estonian: Arst kaalub ioniseerivat kiirgust mitterakendavaid alternatiivseid meetodeid Rasestuda võivad naised peavad ravi ajal ja pärast ravi kasutama tõhusat rasestumisvastast meetodit.
English: EU/1/05/322/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/05/322/001
English: Y)-labelled medicinal product is dependent on the specific medicinal product being radiolabelled.
Estonian: Y) märgistatava ravimipreparaadi kogus sõltub radiomärgistatavast ravimipreparaadist ja kasutuseesmärgist.
English: Yttriga is intended for radiolabelling of medicinal products to treat specific diseases, which are subsequently administered by approved route.
Estonian: Yttriga'ga märgistatakse radioaktiivselt teatud haiguste ravis kasutatavaid ravimeid, mida seejärel manustatakse ettenähtud viisil.
English: Storage should be in accordance with national regulation on radioactive material.
Estonian: Hoiutingimused peavad olema kooskõlas kohalike radioaktiivseid materjale puudutavate määrustega.
English: Storage should be in accordance with local regulations for radioactive substances.
Estonian: Hoiutingimused peavad olema kooskõlas kohalike radioaktiivseid aineid puudutavate seadustega.
English: 7.90 E-02 1.18 E-01 2.76 E-01 3.95 E-01 7.90 E-01 2.37 E+00 Skeletal muscle 6.12 E-04 9.17 E-04 2.14 E-03 3.06 E-03 6.12 E-03 1.83 E-02 Skin
Estonian: 7,90 E-02 1,18 E-01 2,76 E-01 3,95 E-01 7,90 E-01 2,37 E+00 Vöötlihased 6,12 E-04 9,17 E-04 2,14 E-03 3,06 E-03 6,12 E-03 1,83 E-02 Nahk
English: Dose Your physician will decide on the amount of Yttriga, which you will receive for the treatment.
Estonian: Annus Arst määrab teile ravi käigus manustatava Yttriga koguse.
English: PHARMACEUTICAL FORM AND CONTENTS Radiopharmaceutical precursor, solution.
Estonian: RAVIMVORM JA PAKENDI SUURUS Radiofarmatseutiline prekursor, lahus.
English: Femur
Estonian: Emakas
English: Heart
Estonian: Aju
English: - if you are allergic (hypersensitive) to Yttrium (90Y) chloride or any of the other ingredients of
Estonian: Ärge kasutage Yttriga't: - kui te olete ülitundlik (allergiline) ütriumkloriidi (90Y) või Yttriga mõne koostisosa suhtes.
English: TIN CAN AND LEAD POT
Estonian: MANUSTAMISVIIS JA -TEE
English: Yttriga is intended for in vitro labelling of medicinal products which are subsequently administered by the approved route.
Estonian: Yttriga on mõeldud ravimite märgistatamiseks in vitro.
English: 6.6 Special precautions for disposal
Estonian: 6.6 Säilitamise eritingimused
English: Liver uptake decreases then to 8.4 % 24 hours after injection.
Estonian: Edasise 24 tunni jooksul väheneb aktiivsus maksas 8,4 %-le.
English: There are no data available on the toxicity of Yttrium (90Y) chloride nor on its effects on reproduction in animals or its mutagenic or carcinogenic potential.
Estonian: Manustamiseelselt Yttriga'ga radiomärgistatud ütriumiga (90Y) märgistatavate ravimipreparaatide toksikoloogilised omadused olenevad radiomärgistatava ravimipreparaadi omadustest Ütriumkloriidi (90Y) toksilisuse, toimete kohta loomade reproduktsioonile ja võimalike mutageensete ning kartsinogeensete omaduste kohta andmed puuduvad.
English: Further information concerning the use of a Yttrium (90Y)-labelled medicinal products in pregnancy and breast-feeding is specified in the Summary of Product Characteristics of the medicinal product to be radiolabelled.
Estonian: Lisateavet ütriumiga (90Y) märgistatavate ravimipreparaatide kasutamise kohta raseduse ja imetamise ajal vaadake vastava radiomärgistatava ravimi ravimi omaduste kokkuvõttest.
English: Information on radiation dosimetry of each different medicinal product following administration of the radiolabelled preparation will be available in the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Estonian: Radiomärgistatava preparaadi manustamise järgsed kiiritusdoosi andmed iga preparaadi kohta on toodud radiomärgistatava ravimipreparaadi ravimi omaduste kokkuvõttes/pakendi infolehes.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND MANUFACTURER
Estonian: • MÜÜGILOA HOIDJALE ESITATUD HANKE- JA KASUTUSTINGIMUSED JA
English: The administration of radioactive medicinal products creates risks for other persons from external radiation or contamination from spills of urine, vomiting, etc.
Estonian: Radioaktiivsete ravimipreparaatide väline kiirgus või kokkupuude patsiendi uriini, oksemasside vmsga kujutab ohtu kõrvalistele isikutele.
English: Each 10ml vial contains 0.1-300 GBq, corresponding to 0.005-15 micrograms of Yttrium (90Y), at reference date and time.
Estonian: Üks 10 ml viaal sisaldab referentskuupäeval ja -kellaajal 0,1-300 GBq, mis vastab 0,005-15 mikrogrammile ütriumile (90Y).
English: Stomach
Estonian: Magu
English: Each 3ml vial contains 0.1-300 GBq, corresponding to 0.005-15 micrograms of Yttrium (90Y), at reference date and time.
Estonian: Üks 3 ml viaal sisaldab referentskuupäeval ja -kellaajal 0,1-300 GBq, mis vastab 0,005-15 mikrogrammile ütriumile (90Y).
English: 7.23 E-01 1.09 E+00 2.53 E+00 3.62 E+00 7.23 E+00 2.17 E+01
Estonian: Neerupealised 7,23 E-01 1,09 E+00 2,53 E+00 3,62 E+00 7,23 E+00 2,17 E+01 Veri
English: Kidneys
Estonian: Kusepõis
English: For more information, refer to the package leaflet of the particular medicinal product to be radiolabelled.
Estonian: Täpsemat teavet vaadake radiomärgistatava ravimipreparaadi pakendi infolehest.
English: Act.: {Y}________GBq/vial Cal.: {DD/MM/AAAA} (12h CET)
Estonian: : {Y}________GBq/viaal Kal.
English: please tell your doctor or pharmacist.
Estonian: mida selles infolehes ei ole nimetatud, palun rääkide sellest oma arstile või apteekrile.
English: For information concerning special warnings and special precautions for use of Yttrium (90Y)-labelled medicinal products refer to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Estonian: Ütriumiga (90Y) märgistatavaid ravimipreparaate puudutavaid hoiatusi ja ettevaatusabinõusid vaadake vastavate radiomärgistatavate ravimite ravimi omaduste kokkuvõttest/pakendi infolehest.
English: NAME OF THE MEDICINAL PRODUCT Yttriga radiopharmaceutical precursor, solution.
Estonian: RAVIMPREPARAADI NIMETUS Yttriga radiofarmatseutiline prekursor, lahus.
English: 4.7 Effects on ability to drive and use machines Effects on ability to drive and to use machines following treatment by Yttrium (90Y)-labelled medicinal products will be specified in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Estonian: Ütriumiga (90Y) märgistatavate ravimipreparaatide toimeid autojuhtimisele ja masinate käsitsemise võimele vaadake vastavate radiomärgistatavate ravimite ravimi omaduste kokkuvõttest/pakendi infolehest.
English: Ovaries
Estonian: Luustik
English: The pharmacodynamic properties of Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with Yttriga, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Estonian: Enne manustamist Yttriga'ga radiomärgistatud ütriumiga (90Y) märgistatavate ravimite farmakineetilised omadused olenevad radiomärgistatava ravimipreparaadi omadustest.
English: - 1 ml sterile solution contains 0.1-300 GBq Yttrium (90Y) on the reference date and time
Estonian: - 1 ml steriilset lahust sisaldab referentskuupäeval ja kellaajal 0,1-300 GBq ütriumi (90Y) (vastab
English: Blood
Estonian: Maks
English: Further information concerning the use of a Yttrium (90Y)-labelled medicinal concerning fertility is specified in the Summary of Product Characteristics of the medicinal product to be radiolabelled.
Estonian: Fertiilsus Lisateavet ütriumiga (90Y) märgistatavate ravimipreparaatide ja fertiilsuse kohta vaadake vastava radiomärgistatava ravimi ravimi omaduste kokkuvõttest.
English: For information concerning interactions associated with the use of Yttrium (90Y)-labelled medicinal products refer to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Estonian: Ütriumiga (90Y) märgistatavaid ravimipreparaate puudutavaid koostoimeid vaadake vastavate radiomärgistatavate ravimite ravimi omaduste kokkuvõttest/pakendi infolehest.
English: For information on contraindications to particular Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with Yttriga refer the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Estonian: Yttriga'ga radiomärgistatud ütriumiga (90Y) märgistatavate ravimite vastunäidustusi lugege vastava radiomärgistatava preparaadi ravimi omaduste kokkuvõttest/pakendi infolehest.
English: PHARMACEUTICAL PARTICULARS 6.1 List of excipients Hydrochloric acid (0.04 M) 6.2 Incompatibilities
Estonian: ABIAINED Vesinikkloriidhape (0,04 M)
English: The dosimetry table below is presented in order to evaluate the contribution of non-conjugated Yttrium (90Y) to the radiation dose following the administration of Yttrium (90Y)-labelled medicinal product or resulting from an accidental intravenous injection of Yttriga.
Estonian: Y) osa kiiritusdoosis pärast ütriumiga (90Y) märgistatavate ravimipreparaatide manustamist või kui Yttriga't on tahtmatult süstitud veeni.
English: BEFORE YOU USE YTTRIGA
Estonian: MIDA ON VAJA TEADA ENNE YTTRIGA KASUTAMIST
English: For further information regarding the treatment and possible effects caused by the radiolabelled medicinal product, please refer to the package leaflet of the medicinal product used as combination partner.
Estonian: Lisateavet ravi ja radiomärgistatava ravimi põhjustatud kõrvaltoimete kohta leiate radiomärgistatava ravimi pakendi infolehest.